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Abstract
It is well recognized that poor muscle function and poor physical performance are strong predictors of clinically relevant 
adverse events in older people. Given the large number of approaches to measure muscle function and physical performance, 
clinicians often struggle to choose a tool that is appropriate and validated for the population of older people they deal with. 
In this paper, an overview of different methods available and applicable in clinical settings is proposed. This paper is based 
on literature reviews performed by members of the European Society for Clinical and Economic Aspects of Osteoporosis and 
Osteoarthritis (ESCEO) working group on frailty and sarcopenia. Face-to-face meetings were organized afterwards where the 
whole group could amend and discuss the recommendations further. Several characteristics should be considered when choos-
ing a tool: (1) purpose of the assessment (intervention, screening, diagnosis); (2) patient characteristics (population, settings, 
functional ability, etc.); (3) psychometric properties of the tool (test–retest reliability, inter-rater reliability, responsiveness, 
floor and ceiling effects, etc.); (4) applicability of the tool in clinical settings (overall cost, time required for the examination, 
level of training, equipment, patient acceptance, etc.); (5) prognostic reliability for relevant clinical outcomes. Based on these 
criteria and the available evidence, the expert group advises the use of grip strength to measure muscle strength and the use of 
4-m gait speed or the Short Physical Performance Battery test to measure physical performance in daily practice. The tools pro-
posed are relevant for the assessment of muscle weakness and physical performance. Subjects with low values should receive 
additional diagnostic workups to achieve a full diagnosis of the underlying condition responsible (sarcopenia, frailty or other).
Keywords Muscle function · Muscle strenght · Physical performance · Daily practice · Sarcopenia
Introduction
In 2015, WHO proposed a new vision for healthy ageing in its 
World Report on Ageing and Health. The report defines the 
goal of healthy ageing as helping people in “developing and 
maintaining the functional ability that enables well-being”. 
Functional ability is determined by the intrinsic capacity of 
the individual, relevant environmental characteristics and the 
interactions between them. Although actions at all levels of 
the society are vital to foster healthy ageing, realigning health 
systems towards building and maintaining the intrinsic capac-
ity and functional abilities of adults in the second half of life 
has been identified as an immediate priority.
Significant loss of intrinsic capacity (functioning) in 
older adults is characterized by the manifestation of com-
mon problems, such as difficulties walking at usual pace, 
loss of muscle mass and strength and mobility impairments 
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[1]. At present, most health care professionals lack guid-
ance or training to recognize and manage declines in phys-
ical capacities in older age. However, research evidence 
suggests that even in less resourced health care settings, 
health care professionals can be trained to detect declines 
in physical capacities (clinically expressed as mobility 
impairments) and deliver effective interventions to prevent 
and delay progression [2].
In 2017 WHO launched the Guidelines on community 
level interventions to manage declines in intrinsic capacity. 
The primary audience for these WHO-ICOPE guidelines 
on community-level interventions is health care providers 
working in primary and secondary care settings (http://
www.who.int/agein g/publi catio ns/guide lines -icope /en/). 
Guidance on the assessment of physical performance in 
daily clinical practice can be helpful for geriatricians and 
for physicians working with frail elderly subjects.
Considering the large number of tools available to 
measure physical function in older adults, including mus-
cle mass and strength, WHO requested support from the 
World Health Organization, Collaborating Center for Pub-
lic Health Aspects of Musculoskeletal Health and Aging 
to undertake an initial review and consultation towards the 
identification of the most appropriated tools. As measures 
of muscle strength and physical performance are increas-
ingly used for research and practice, a review and identi-
fication of appropriated tools to evaluate them is timely. 
The findings presented in this paper are result of a fruitful 
collaboration between experts of the European Society for 
Clinical and Economic Aspects of Osteoporosis, Osteo-
arthritis and Musculoskeletal Diseases (ESCEO) and the 
World Health Organization, Collaborating Center for Pub-
lic Health Aspects of Musculoskeletal Health and Aging. 
In this paper, an overview of different methods available 
and applicable in clinical settings is proposed. The WHO 
Strategy aims to encourage clinicians and general practi-
tioners (GPs) working in primary health care settings to 
timely identify declines in muscle strength and physical 
performance on in older adults. This process should be fol-
lowed by a precise diagnosis and the start of interventions 
in affected individuals [3]. The respective measures can be 
categorized as primary or secondary prevention in older 
persons that are at high-risk of future care dependence.
It is important to clarify the terms muscle function and 
physical performance. Muscle function first is underlined 
by the three concepts of muscle strength, muscle power and 
muscle endurance. Muscle strength refers to” the amount of 
force a muscle can produce with a single maximal effort”. 
Muscle strength should be differentiated to muscle power 
which is defined by “the ability to exert a maximal force 
in as short a time as possible, as in accelerating, jumping 
and throwing implements” and to muscle endurance which 
is defined as “the ability of muscles to exert force against 
resistance over a sustained period of time”. The concept 
of physical performance has become confusing along time 
and merits a new vision. When first defined, physical per-
formance measures were used to objectively assess how 
an individual performed different activities of daily living 
(ADLs) or physical tasks in the clinic, as opposed to ADL 
scales based on asking questions about the ability to perform 
such tasks. However, in the last decades, this old concept 
has gradually changed, and measures of physical perfor-
mance are now mostly related to ambulation and transfers. 
In fact, some measures of physical performance (i.e. gait 
speed) have become part of the definitions of frailty and 
sarcopenia. No definition of this updated concept of physi-
cal performance exists. After long discussion, the group 
developed a definition of physical performance definition 
which describes it as “an objectively measured whole body 
function related with mobility”. Physical performance goes 
beyond muscle function measures, as it involves many other 
body organs and systems (bones, balance and other neuro-
logical inputs, cardiovascular aspects, motivation…) being 
a multidimensional concept (Fig. 1). It is thus linked to the 
WHO concept of intrinsic capacity in its aspects related with 
mobility. Impairments in physical performance may be evi-
dent way before disability starts (as defined by inability to 
perform ADLs), so it allows for detection of vulnerability 
in the first steps of the disabling cascade. Physical perfor-
mance is different from physical capacity where the notion 
of capacity to achieve is primordial.
In order to make this paper easy to consult for clinicians, 
the authors chose to focus on tests that clinicians are sus-
ceptible to use in their daily practice instead of presenting 
a review of all available tests in the literature, including 
some not suitable for routine assessments. The instruments 
included in this paper were a consensus decision of the 
ORGAN FULL BODY INDIVIDUAL
Muscle funcon 
(strength, power)
Physical performance Acvies of daily living
Fig. 1  Hierarchy of loss of physical function
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authors after reviewing all the evidence on the tools avail-
able. They took into account multiple criteria, such as the 
availability of the tool, the presence of validated protocols 
for measurement and cut-offs, etc. Ultimately, they agreed 
to present the most applicable tests for clinical assessments.
Methods
As in previous initiatives [4–6], the European Society for 
Clinical and Economic Aspects of Osteoporosis and Osteo-
arthritis (ESCEO) working group on frailty and sarcope-
nia consists of clinical scientists and experts in the field of 
musculoskeletal diseases. Different members of the ESCEO 
working group were asked to review the literature on (1) 
tools to assess muscle strength and power in daily practice—
strengths and weaknesses (JB); (2) objective assessment of 
muscle strength and power (CS); (3) tools to assess physical 
performance in daily practice—strengths and weaknesses 
(ACJ); and (4) can reference standards in the assessment of 
muscle strength, muscle power and physical performance 
be developed? (RF). Randomized controlled trials, prospec-
tive studies, systematic reviews and meta-analyses published 
before September 2017 were sought on PubMed and Scopus 
using the following search terms: (1) Mesh terms searched: 
Aged, Muscle skeletal, Muscle strength, Physical functional 
performance, Gait, Walk test, Walking, Sarcopenia, Refer-
ence standards, Reference Values; (2) Additional terms 
searched in either title, abstract or keywords: muscle power, 
physical function, endurance test. Additional studies were 
identified through the expertise of the members of the work-
ing group but also by a manual search of the reference sec-
tions of relevant articles and existing reviews. Each member 
prepared a list of the most important papers based on their 
review of the literature and then created a set of preliminary 
recommendations. The subsequent step was a face-to-face 
meeting of the whole group to make amendments and dis-
cuss results. Shared conclusions were reached and finalized 
during the creation of the current manuscript whose drafts 
were circulated by mail (Fig. 2).
Measurement of Muscle Function
Muscle Strength
There are few well-validated techniques to measure muscle 
strength. Among them, strength of both upper limbs and 
lower limbs can be assessed; both of them having been 
shown to be highly correlated [7–10]. In clinical settings 
and for the diagnosis of sarcopenia and frailty, grip strength 
is the measure of choice for the assessment of overall muscle 
strength, as it has been shown to be a surrogate for lower 
extremity muscle strength and as it is easier to measure [5, 
10, 11]. Indeed, grip strength measurement only requires 
the holding of a handheld dynamometer, has standardized 
protocols of measurement and has robust and validated 
cut-offs values available, which is not the case for all lower 
limb muscle strength values. The common use of hand-
grip strength in clinical daily practice has been highlighted 
recently in a survey based on the experience of 255 clini-
cians from 55 countries showing a large part of the sample 
using handgrip strength (66.4% of the sample) compared to 
lower limb muscle assessments (e.g. leg press 24.2%, chest 
press 9.4%, isokinetic parameters 7.4% of the sample) [12]. 
For these reasons, this consensus paper focused only on grip 
strength as the measure of muscle strength, following the 
recommendation of the experts involved in this paper.
Grip Strength
Definition
Handgrip strength is the most widely used method for the 
measurement of muscle strength. It is recognized to be easily 
applicable both in research and in clinic settings [5]. Hand-
grip strength is usually measured during muscular isotonic 
contraction.
How to Measure Grip Strength in Clinical Practice?
• Procedure The measurement is easy to perform, the 
device is portable, with an acceptable cost, and does not 
require a specialist trained user. Because of the ease of 
its application, grip strength measurement can be used 
in clinical practice, and thus, can be applied in a large 
sample of older adults, symptomatic or asymptomatic, 
to identify those with low muscle strength. It is recom-
mended to use standardized measurement protocols such 
the Southampton protocol, proposed by Roberts et al. [13, 
14] for the measurement of grip strength. Briefly, stand-
ardized conditions for the test include seating the subject 
in a standard chair with forearms resting flat on the chair 
arms. The testing nurse or physician should demonstrate 
the use of the dynamometer and show that gripping very 
tightly registers the best score. Six measures should be 
taken, 3 with each arm. Ideally, the patients should be 
encouraged to squeeze as hard and as tightly as possible 
during 3–5 s during each of the 6 trials; usually the high-
est reading of the 6 measurements is reported as the final 
result.
• Time of administration 5 min.
• Equipment A well-calibrated handheld dynamometer. 
Different features exist such as hydraulic dynamometer 
[e.g. Jamar, which is usually considered as the gold 
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reference for this measurement, with units in kilograms 
(kg) or pounds (lbf)], pneumatic [e.g. Martin vigorim-
eter with units in millimetres of mercury (mmHg) or 
pounds per square inch (psi)] which measure grip pres-
sure, mechanical [e.g. Harpenden dynamometer with 
units in kg or lbf) and strain dynamometer (with units 
in Newtons of force (N)]. Dynamometers have to be 
calibrated appropriately by manufacturer prior using it 
[15].
Performance Characteristics
• Highly feasible [16].
• Test–retest reliability in older adults is good (ICC ≥ 0.85) 
[17, 18].
• Inter-rater reliability in older adult is excellent (ICC 
0.95–0.98) [16, 19].
• Responsiveness One study proposed a minimal change of 
6 kg (13.2 lb) to be considered as significant [20]. Data 
on sensitivity of change in grip strength to interventions 
are still rather limited and inconsistent [18, 21].
• Floor effects For patients with upper extremity impair-
ment and/or affected by rheumatoid arthritis, hand 
osteoarthritis or carpal tunnel syndrome, grip strength 
measure may not be an accurate reflection of muscle 
strength and may lead to underestimations. The design 
of the Jamar dynamometer may be the reason for this [22] 
and a pneumatic dynamometer may be a good alterna-
tive for these patients. With the Martin vigorimeter for 
example, patients try to squeeze rubber balls (available in 
three sizes) following the same protocol as that described 
for the Jamar dynamometer. However, the comparison 
between these two devices is limited given the different 
unit of measure provided by them.
• Note that the absolute values and the precision of grip 
strength measurement are influenced by hand position, 
hand size and dominance [23], body position [24] verbal 
encouragement [25] and patient motivation. For this rea-
son, the application of a standardized protocol is highly 
recommended [13].
Reference Range
• Variety of normative data have been proposed, ranging 
from 16 to 21 kg for women and 26 to 30 kg for men [10, 
26–29]. It should also be noted that values adjusted for 
BMI or height also exists. For example, the EWGSOP 
[27] proposed general values for grip strength (< 30 kg 
for men and < 20 kg for women) but also BMI depend-
ent value (e.g. ≤ 29 kg for men with a BMI ≤ 24 kg/m2; 
≤ 30 kg for men with a BMI between 24.1 and 28 kg/
m2; ≤ 32 kg for men with a BMI > 28 kg/m2; ≤ 17 kg for 
women with a BMI ≤ 23 kg/m2; ≤ 17.3 kg for women 
with a BMI between 23.1 and 26 kg/m2; ≤ 18 kg for 
women with a BMI between 26.1 and 29 kg/m2 and 
finally ≤ 21 kg for women with a BMI > 29 kg/m2).
• Low grip strength is consistently associated with poor 
outcomes; care dependence, falls, fractures, mortality 
[30–35].
Muscle power
Compared to muscle strength, power concerns work rate 
(work done per unit time). In healthy older people, mus-
cle power declines earlier and faster compared to muscle 
mass and strength [36]. Leg power has been shown to be 
highly correlated with physical performance tests such as 
gait speed, chair stand test and stair-climb time [37], and 
several comparative studies have found that muscle power is 
a better predictor of mortality compared to muscle strength 
[38]. Therefore, muscle power is often proposed as the 
primary therapeutic target for resistance training interven-
tions in older adults. Muscle power can be assessed across 
a range of muscle groups, but most often the leg press and 
knee extension exercises are used to measure muscle power. 
Maximal strength is quantified through the 1RM (1 repeti-
tion maximum resistance), wherein the evaluation is car-
ried out at the highest resistance for which the subject can 
complete the exercise once. To find the 1RM, the exercise is 
repeated several times at increasing resistance until failure 
to complete a single repetition. However, there is a distinct 
lack of standardization across studies, and different equip-
ment and measurement techniques have been used [39]. 
The most common muscle power exercises, leg press and 
knee extension, show good reliability and validity [40]. Cur-
rently, a reference range for the different measures of mus-
cle power is not yet available. Because measuring muscle 
power requires complex and sometimes expensive machines 
but also because the applicability of this measure is com-
promised in clinical settings (necessity of training for both 
clinicians and subjects, time-consuming, no standardized 
protocols available, etc.) and finally, because standardized 
cut-off points have not been agreed to define a low muscle 
power, muscle power assessments can hardly be considered 
useful in daily practice. For this reason, based on an agree-
ment of the experts involved in this paper, measurement of 
muscle power will not be exhaustively discussed in the pre-
sent paper.
Measurement of Physical Performance
Many tests are described in the literature to measure physical 
performance of older adults. Considering the applicability 
of these tests in clinical practice but also their performance 
characteristics, the experts involved in this paper agreed to 
5Assessment of Muscle Function and Physical Performance in Daily Clinical Practice 
1 3
focus on some of the available physical performance tests. 
They therefore chose to present and encourage the measure-
ment of gait speed, chair stand test, short physical perfor-
mance battery (SPPB) test and the timed up and go (TUG) 
test.
Gait Speed Test
Two main types of gait speed tests exist; the short-distance 
walk tests (2.4-m distance, 4-m distance, 6-m distance and 
10-m distance) and the long-distance walk tests (400-m walk 
test and 6-min walk test). Long-distance walk tests require 
a corridor of at least 20 m as well as a minimum time for 
execution of 15 min. These tests may be extremely useful in 
discriminating different categories of risk among older indi-
viduals in healthy conditions. Besides measuring physical 
performance in older adults, these tests also evaluate endur-
ance of the subjects. Nevertheless, short walk tests can be 
used as surrogates for long-distance walk tests to measure 
the overall functional status in older adults [41]. Indeed, 
the 4-m gait speed test, for example, has been shown to be 
highly predictive of the ability to perform the 400-m walk 
test in older adults [41, 42]. Taking this into account and 
because short-walk tests are clearly more readily applicable 
in clinical settings, the experts of this group agreed to focus 
on short walk tests for the current review and strongly rec-
ommend these tests to assess physical performance of older 
adults in routine practice.
Short Walk Measures of Usual Gait Speed
Definition
The gait speed measurement is probably one of the most 
widely used tools in clinical practice for the assessment of 
physical performance. It is generally measured in a short 
distance (2.4-m distance, 4-m distance, 6-m and 10-m dis-
tance) with the 4-m distance as being the most commonly 
used short-walk test validated in older adults.
How to Measure Gait Speed Test in Clinical Practice?
• Procedure short-distance walk tests are applicable in 
clinics and in GPs offices but some training for the testing 
staff is required. This measure is also highly acceptable 
for participants and health professionals [43, 44]. Some 
tentative recommendations for a protocol of administra-
tion have been proposed following a systematic review 
[45]: (1) use a static start with timing commencing when 
the foot touches the floor the first time after the line; (2) 
usual or comfortable pace to be used as the standard, 
with fast pace used as appropriate for specific research 
questions. (3) Walking protocol to be reported in detail 
including pace instructions, verbal or other encourage-
ment, and specific timing procedures.
• Time of administration 95 ± 20 s.
• Equipment 4-m long flat floor devoid of obstacles and a 
chronograph. This test can therefore be administered in 
restricted areas.
Performance Characteristics
• Test–retest reliability excellent test–retest reliability on 
4- and 10-m distance has been shown for healthy older 
adults (ICC values ranging from 0.96 to 0.98) [46]. Test–
retest reliability of gait speed has also been assessed in 
populations with comorbidities such as in patients with 
stroke [47], COPD [48], in cardiac rehabilitation [49], 
etc. It has been demonstrated to be highly reliable in each 
of these populations.
• Inter-rater reliability very strong inter-rater reliability 
reported in older patients with COPD ICC value of 0.99 
(95% CI 0.98–0.99) [48, 50].
• Responsiveness the 4-m gait speed is responsive to clini-
cally meaningful changes with 0.05 m/s denoting a small 
change (i.e. clinically detectable, potentially important) 
and 0.1 m/s indicating a substantial change (clinically 
detectable, definitely important) [51].
• Floor effect A floor effect is obvious in subjects unable 
to walk. However, as it has been shown in a system-
atic review, there is a broad range of people for whom 
timed walking is a valid and sensitive outcome meas-
ure (patients with cancer, neurological problems, osteo-
arthritis, fractures, etc.) [45]. A ceiling effect has also 
been reported in certain populations. For example, it is 
doubtful whether a potential increase of muscle mass will 
result in an improvement in gait speed in well-function-
ing subjects with a high baseline walking speed.
Reference Range
• Timed usual gait has been shown to be highly predic-
tive for future care dependence [52], for other adverse 
health events such as severe mobility limitation or mor-
tality [53]. But it has also been demonstrated that poor 
performance in other tests of lower extremity function 
(standing balance test and chair rise test) had comparable 
prognostic value [54].
• Cut-off < 0.8 m/s for 4-m distance identifies subjects with 
poor physical performance [10]. A systematic review 
including 3 studies with 3261 participants revealed a 
very high sensitivity for the < 0.8 m/s cut-off for iden-
tifying frailty (Se = 0.99), as well as high negative pre-
dictive value (NPV = 0.99), but also a moderate speci-
ficity (Sp = 0.64) and a low positive predictive value 
(PPV = 0.26) [55].
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• Cut-off < 1 m/s for a 6-m distance identifies older persons 
at high risk of health-related negative events [54].
• Other cut-offs, adapted for example, to the height of 
participants has also been proposed by Fried et al. on a 
distance of 15-ft (4.572 m) [17, 73].
Chair Stand Test
Definition
The 30-second (30-s) Chair stand test (CST) developed by 
Rikli and Jones [56] is one of the most important physical 
performance clinical tests because it measures lower body 
power, balance and endurance and relates it to the most 
demanding daily life activities. The 30-s CST has been 
widely used in many studies not only to evaluate functional 
fitness levels [57] but also to monitor training [58–60] and 
rehabilitation [61]. Another version of the chair stand test 
is also well known (as it is embedded in the SPPB) and 
consists of recording the amount of time to complete five 
sit-to-stand manoeuvers. The test has been shown as a pre-
dictor of falls but has some limitations. This test has indeed a 
restricted capacity to assess a wide variation in ability, which 
is relevant in older people, since some older adults cannot 
complete the five attempts and are therefore not assigned a 
score (floor effect). The utility of this test is therefore limited 
in subjects suffering from moderate to severe mobility limi-
tations. Consequently, for older populations, the literature 
favours time-based protocols such as the 30-s chair stand 
test.
How to Measure the 30‑s CST Test in Clinical Practice?
• Procedure: Classically, the 30-s CST consists of manu-
ally counting the number of total sit-stand-sit cycles 
completed during the 30 s of the test. This test is highly 
feasible in clinical practice and may therefore be recom-
mended as a measure of physical performance.
• Time of administration 1–2 min.
• Equipment A chair with a straight back without arm rests 
and a stopwatch.
Performance Characteristics
• Test–retest reliability good test–retest reliability (0.84 for 
men to 0.92 for women) in healthy older adults [62] as 
well as excellent reliability for subjects with knee arthro-
plasty [63], for subjects with mild-to moderate dementia 
[64] or hospitalized patients with stroke [65].
• Inter-rater reliability limited data available but very 
strong inter-rater reliability on older adults in nursing 
home with mild to moderate dementia (perfect ICC of 1) 
[64].
• Responsiveness Very limited data available. Only a min-
imal detectable change (MDC) value of 3.49 in older 
people with dementia [66] has been defined. Then, an 
improvement in more than 3.49 sit-stand-sit cycles dur-
ing the 30-s chair stand test is considered to be a true 
change in performance with 95% confidence.
• Floor effect this test is not impacted by floor effect, as 
it is the case of the five sit-to-stand test, since subjects 
unable to perform it are attributed a score of 0. Some 
authors argue that the 30-s CST protocol makes it pos-
sible to assess wider variations in ability levels of indi-
viduals compared to the five-time sit-to-stand test as it 
avoid potential floor effects [67].
Reference Range
• Limited data in literature.
• One author report an association between the test and 
the risk of falling in a population of older nursing home 
residents [68].
• Normative values have been proposed for two particu-
lar populations: Hong Kong older adults and US older 
adults. Normative value for Hong Kong older adults 
70–74 years for example is a mean of 10.1 ± 3.8 stands 
during 30-s and 13 stands during 30 s for US norms [69].
Short Physical Performance Battery (SPPB)
Definition
The short physical performance battery (SPPB) originally 
developed at the National Institute on Aging for use in the 
Established Population for the Epidemiologic Studies of 
the Elderly (EPESE) [70] is the most widely used physical 
performance test battery that has been applied in clinical 
and research settings including randomized controlled trials. 
This battery of tests has been validated in large-scale epide-
miological studies and evaluates lower extremity functional 
performance using timed measures of standing balance, 
gait speed and lower extremity strength. Moreover, both the 
global score and its individual elements may be analysed 
separately in different clinical or research settings.
How to Measure SPPB Test in Clinical Daily Practice?
• Time of administration 10 min.
• Equipment a 4-m track, ground marks, a chronometer and 
straight-backed chair.
• Procedure applicable in research and in clinics as well as 
in GPs offices but training is required. The full detailed 
instructions can be downloaded for free from the web 
(https ://sppbg uide.com/) but are summarized here below. 
This test is longer to apply compared to chair rising test 
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alone or to gait speed test alone but is nevertheless feasi-
ble and can be recommended as a screening test for poor 
physical performance and risk of sarcopenia.
The three following tests should be administrated succes-
sively in the same order as they are presented below:
1. Balance test
  For the balance test, the subject is asked to hold three 
increasingly challenging standing positions for 10 s 
each: (1) a side-by-side position; (2) semi-tandem posi-
tion (the heel of one foot beside the big toe of the other 
foot); (3) tandem position (the heel of one foot in front 
of and touching the toes of the other foot).
2. Walking speed test
  For the walking speed test, the subject is asked to 
walk at his/her usual pace over a 4-m course (originally 
8 feet or 2.4 m). He/she is instructed to stand with both 
feet touching the starting line and to start walking after a 
verbal command. The subject is allowed to use walking 
aids (cane, walker, or other walking aid) if necessary, 
but no assistance by another person can be provided. 
Timing begins when the starting command is given, and 
time in seconds needed to complete the entire distance is 
recorded. The faster of two walks is usually considered 
in computing the SPPB score.
3. Repeated chair stands test
  The repeated chair stands test is performed using a 
straight-backed chair, placed with its back against a wall. 
The subject is first asked to stand from a sitting position 
without using their arms. If he/she is able to perform 
the task, he/she is then asked to stand up and sit down 
five times, as quickly as possible with arms folded across 
their chests. The time to complete five stands is recorded.
  These three physical performance subtasks are used to 
calculate a summary score. The score of each of the three 
tests ranges from 0 to 4, where 4 indicates the best result 
and 0 the worst result. Therefore, a summary score rang-
ing from 0 (worst performers) to 12 (best performers) is 
calculated by adding the categorical results derived from 
the three timed physical performance subtasks.
Performance Characteristics
• Test–retest reliability has been shown to be good to excel-
lent (ICC ranging from 0.83 to 0.92 for measures made 
1 week apart) [71–73]. The reproducibility of the SPPB, 
already very good, can nevertheless be enhanced through 
the use of standardized equipment and an appropriate 
standard operating procedure.
• Inter-rater reliability has been shown to be excel-
lent (ICC 0.91) among acutely admitted older medical 
patients [16]. Data on healthy populations are limited.
• Responsiveness the SPPB is responsive to clinically 
meaningful changes [71, 74] with 0.5 points denoting a 
small change (i.e. clinically detectable, potentially impor-
tant) and 1 point denoting a substantial change (clinically 
detectable, definitely important) [51].
• Ceiling effects it may have ceiling effects for high func-
tioning and very fit older adults (who will score 12 
points). For research, a more challenging SPPB has 
been proposed, for example, in the Health, Aging and 
Body Composition (Health ABC) Study, with time to 
walk 400 m measured instead of 4-m distance, and by 
extending the times from 10 to 30 s for the three standard 
balance tests [54]. This approach is relevant to assess the 
wide range of functioning at baseline among fit older 
participant of cohort studies but is unlikely to be useful 
in clinical practice.
• Floor effects it is still not clear how to score a subject 
unable to walk and therefore unable to perform the SPPB 
test correctly. Floor effects of 0 points may be observed 
in this specific case.
Reference Range
• Scores obtained on a 12-point summary scale provides a 
gradient of functional decline that has been shown to be 
valid and reliable in predicting the future risk of mobility 
impairment, care dependence, institutionalization, hospi-
tal admission and mortality [71, 75, 76].
• Cut-off point of ≤ 10 points has been shown to be a strong 
predictor of the loss of ability to walk 400 meters with a 
sensitivity of 0.69 and a specificity of 0.84 [42].
• Cut-off point of ≤ 8 points has been showed to be associ-
ated with mobility-related disability [52].
• A very low SPPB test (0–6 points) has been shown to be 
associated with increased risk of death [75, 77].
Timed‑Get‑Up‑and‑Go Test
Definition
The timed-get-up-and-go (TUG) test is a physical perfor-
mance measure that has been mainly used to assess gait and 
dynamic balance [78]. It is a single test measuring the time a 
person takes to complete a complex series of different motor 
tasks.
How to Measure the TUG Test in Clinical Daily Practice?
• Procedure Applicable in clinical settings and GPs offices 
and on different populations (with frailty, Parkinson’s 
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disease, cognitive impairment, recent joint surgery, 
osteoarthritis, etc.); little training is necessary.
• TUG requires the subject to stand up from a chair, walk 
three meters, turn around, return and sit down again. The 
stopwatch is started on the word “go” and stopped at the 
moment the subject sits down. The person wears regular 
footwear, uses his/her customary walking aid and walks 
at her/his usual pace. No physical assistance is given. A 
practice trial is given first, and the average time of two 
consecutive trials is recorded.
• Complete instructions can be downloaded in the follow-
ing website: http://foxre hab.org/uploa ds/pdf/2008_Assit 
edLiv ingCo nsult _TUGTe st.pdf. A video provided by the 
Center for Disease Control and Prevention (CDC) is also 
available on the following website: https ://www.youtu 
be.com/watch ?v=BA7Y_oLElG Y.
• Time of administration 2–3 min.
• Equipment Chair with armrest, 3-m track, ground marks, 
stopwatch.
Performance Characteristics
• Test–retest reliability moderate (ICC 0.53) [79] to good 
test–retest reliability (ICC 0.97–0.99) [78, 80, 81] across 
studies.
• Inter-rater reliability excellent in the older population 
(ICC = 0.99 [78], ICC = 0.98 [82]).
• Responsiveness not well defined in older populations. A 
reduction in time greater than or equal to 0.8, 1.4 and 
1.2 s on the TUG has been determined to be the Mini-
mal Important Clinical Change score (MCID) for patients 
suffering from hip osteoarthritis [83].
• Floor and ceiling effects the TUG does not suffer from 
ceiling effects [84]. Floor effects are observed, as for 
each test involving a person’s walking ability.
Reference Range
• The time to perform the task is compared to normative 
values for age, gender, and research-based guidelines that 
measure increased risk of falls and functional decline. 
The performance of the patient can also be summarized 
into a five-point scaled score [85].
• A TUG score of 14 s is sensitive (87%) and specific 
(87%) for identifying older individuals who are at risk 
for falls [82].
• In the systematic review of Clegg et al. [55]., assessing, 
among others, the accuracy of the TUG test for identify-
ing frailty, a sensitivity of 0.93 has been shown for the 
cut-off of > 10 points (with a negative predictive value of 
0.99), with a specificity of 0.62 (with a positive predic-
tive value of only 0.17).
Practice Recommendations
After a review of the literature and discussion during the 
working group meeting, the following statements and recom-
mendations on the use of measures of muscle strength and 
physical performance are proposed:
1. Muscle strength and physical performance measures 
are rarely assessed in daily practice compared to other 
clinical or biochemical parameters. However, limited 
strength and performance result in physical limitations 
which are strong predictors of adverse negative health 
outcomes such as care dependence, falls, fractures, hos-
pitalization and death. Therefore, the experts involved 
in this position paper strongly encourage clinicians to 
routinely assess strength and physical performance in 
older adults. Unfortunately, data do not yet reveal what 
is the ideal frequency of repeated measures. Evidence is 
still needed in this regard.
2. Measurements of muscle strength and function are facili-
tated by their non-invasiveness and their effective lim-
ited time for application.
3. Many different tests to measure muscle strength and physi-
cal performances have been described, although not all 
have the same level of evidence or are easy to use in rou-
tine clinical practices. The experts involved in this paper 
summarized the most widely applicable tests in daily prac-
tice. For measuring muscle strength, the experts advise 
the use of a handheld dynamometer to assess handgrip 
strength. For measuring physical performance, the experts 
advise the assessment of 4-m gait speed, Short Physical 
Performance Battery test or Timed Up and Go test.
4. The choice of the tool to use should be guided according 
to different parameters:
a. The purpose of the assessment should be essential 
in the choice of the clinician. For an intervention, 
it is more important to have a tool with a respon-
siveness to test the impact of an intervention on 
muscle strength and function. Based on the experts’ 
review of the literature, only grip strength, SPPB 
test and gait speed show a sufficient responsiveness 
in general older population. Good responsiveness 
of other tools has also been shown in specific popu-
lation (e.g. population suffering from dementia, 
COPD population, etc.). For a practical purpose, it 
is essential to have a cheap and easy-to-administer 
tool applicable to the majority of older adults. The 
presence of validated normative values for a large 
group of patients, and from different countries, is 
also essential. Based on the experts’ review of the 
literature, validated normative values are mainly 
available for grip strength, gait speed and SPPB 
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test. For diagnosis purposes, the objective is some-
what different and requires therefore a tool with 
robust validity and reliability. Based on the experts’ 
review of the literature, all the tools presented in this 
paper show satisfactory validity and reliability.
b. The population’s characteristics will also determine 
the choice of test. Given the heterogeneity of the 
population in daily practice, it is important to choose 
a tool that is highly practicable in various patients’ 
groups. For older people with significant losses of 
capacity or ability or robust, clinicians should be 
aware of the presence of floor and ceiling effects. 
Based on the experts’ review of the literature, each 
test involving a person’s walking ability is prone to 
floor effects. It is also the case for grip strength, with 
limitations particularly in some patients with local 
disease, for example advanced arthritis. Some adap-
tations of the tests have been proposed in order to 
characterize the wide range of functioning in these 
patients.
c. Applicability in clinical settings (cost, required time 
for the examination, necessary of training, complex 
equipment, etc.). Based on the experts’ review of 
the literature, the two most applicable tools in the 
clinical settings are grip strength measured by a 
handheld dynamometer and the 4-m gait speed. 
Both methods do not require a complex and expen-
sive equipment, are cheap, quick and easy to admin-
ister, do not require a special training of clinicians 
and, for the grip strength measurement mainly, 
standardized validated protocols of assessment are 
available.
d. The performance characteristics of the tools (test–
retest reliability, inter-rater reliability, responsive-
ness, floor and ceiling effects, etc.). Based on the 
experts’ review of the literature, all the proposed 
tools seem reliable but only some of them have 
already been evaluated for responsiveness. The 
SPPB test and the 4-m gait speed test seem to be the 
most robust tools in terms of responsiveness.
e. The prognostic values of the tests for adverse clini-
cal outcomes. Numerous normative data and cut-off 
points for predicting outcomes have been proposed 
for the different tools available, both in healthy older 
population and in specific comorbidities. Based 
on the experts’ review of the literature, currently, 
there is substantial evidence for threshold values 
for handgrip strength, SPPB and 4-m gait speed as 
being strong predictors of adverse negative health 
outcomes.
5. Based on the available evidences, the applicability of 
the tools in clinical practice, the required time for the 
test, the required equipment, the performance charac-
teristics of the tool but also the availability of robust 
cut-off points, the experts advised grip strength to meas-
ure muscle strength and 4-m gait speed or SPPB test to 
measure physical performance in daily practice. Sub-
jects with low strength or performance should receive an 
additional diagnostic workup to achieve a full diagnosis 
of the condition that causes such problems (sarcopenia, 
frailty or other problems).
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